Intravenous Magnesium Sulfate for Severe Acute Asthma
For adults and children with severe acute asthma exacerbations that remain unresponsive after 1 hour of intensive conventional treatment (repeated β-agonists and systemic corticosteroids), administer intravenous magnesium sulfate 2 g over 20 minutes in adults or 25-75 mg/kg (maximum 2 g) over 20-60 minutes in children. 1, 2
When to Administer IV Magnesium Sulfate
The decision to use IV magnesium sulfate should be based on severity and treatment response:
- Life-threatening exacerbations: Consider immediately as adjunctive therapy 1
- Severe exacerbations after 1 hour of standard treatment: This is the primary indication—patients who have received at least 3 doses of inhaled bronchodilators (60-90 minutes of therapy) plus systemic corticosteroids but remain in severe distress 1
- Very severe presentations: Greatest benefit occurs when initial FEV₁ is <25% predicted 3
Do not use in mild-to-moderate exacerbations—there is no apparent value in patients with less severe presentations 1, 3
Dosing Regimen
Adults
- 2 g IV over 20 minutes 1, 2
- Must dilute 50% solution to ≤20% concentration before IV administration 2
- Rate should not exceed 150 mg/minute except in severe cases 2
Children
- 25-75 mg/kg IV (maximum 2 g) over 20-60 minutes 1, 4
- Most evidence supports 40-50 mg/kg as optimal dosing 5, 6
- For every 5 children treated, one hospital admission can be prevented 4
Clinical Context and Evidence Strength
The guideline evidence 1 provides a conditional recommendation for IV magnesium sulfate, meaning it should be selectively used rather than routinely administered. This recommendation is supported by high-quality research showing:
- Reduced hospital admissions: 7 fewer admissions per 100 adults treated (OR 0.75,95% CI 0.60-0.92) 7
- Improved lung function: Significant improvements in FEV₁, PEF, and FEV₁/FVC ratio in both adults and children 5, 7, 3
- Greatest benefit in severe cases: When initial FEV₁ <25% predicted, the final FEV₁ improved by 9.7% compared to placebo 3
The evidence is strongest for single-dose bolus therapy. While some centers use continuous infusions for refractory status asthmaticus, this approach lacks robust evidence and should be reserved for exceptional cases 8.
Monitoring Requirements
Before and during administration, assess:
- Patellar reflex (knee jerk): Must be present before each dose; absence indicates magnesium toxicity 2
- Respiratory rate: Should be ≥16 breaths/minute 2
- Urine output: Maintain ≥100 mL in 4 hours preceding dose 2
- Serum magnesium levels: Therapeutic range 3-6 mg/100 mL (2.5-5 mEq/L); reflexes diminish >4 mEq/L, respiratory paralysis risk at 10 mEq/L 2
Safety Profile and Adverse Events
Common but generally mild adverse events include 7:
- Flushing and warmth
- Fatigue
- Nausea
- Headache
- Hypotension (particularly with rapid infusion)
Critical safety considerations:
- Have injectable calcium salt immediately available to counteract potential magnesium toxicity 2
- Use with extreme caution in patients with renal impairment—maximum 20 g/48 hours in severe renal insufficiency 2
- Avoid in digitalized patients due to risk of heart block 2
- Do not use beyond 5-7 days in pregnancy—can cause fetal skeletal abnormalities 2
Common Pitfalls to Avoid
Administering too early: Magnesium is not first-line therapy. Ensure patients have received adequate β-agonists and corticosteroids first 1
Using in mild-to-moderate cases: No benefit demonstrated when initial FEV₁ ≥25% predicted 3
Infusing too rapidly: Can cause dangerous hypotension and cardiac effects 2
Failing to monitor reflexes: Loss of patellar reflex is the earliest clinical sign of toxicity 2
Inadequate dilution: The 50% solution must be diluted to ≤20% for IV use 2
Integration with Standard Therapy
IV magnesium sulfate is adjunctive therapy only—it does not replace:
- Oxygen to maintain SpO₂ ≥90%
- Repeated inhaled short-acting β-agonists
- Systemic corticosteroids (oral or IV)
- Ipratropium bromide (can be co-administered) 1, 4
The addition of magnesium to this standard regimen provides incremental benefit in severe cases, particularly reducing the need for hospital admission 7, 9 and non-invasive ventilation 9.